Pfizer Inc. has announced the successful completion of a public debt offering through its subsidiary, Pfizer Netherlands International Finance B.V. The issuance comprises four sets of senior unsecured notes, each guaranteed by Pfizer Inc. The details of the offerings are as follows: 1. €750,000,000 aggregate principal amount of 2.875% Notes due 2029. 2. €1,000,000,000 aggregate principal amount of 3.250% Notes due 2032. 3. €750,000,000 aggregate principal amount of 3.875% Notes due 2037. 4. €800,000,000 aggregate principal amount of 4.250% Notes due 2045. This offering was executed under a shelf registration statement on Form S-3, which was originally filed with the Securities and Exchange Commission on February 23, 2024, and amended on May 13, 2025. The notes were issued on May 19, 2025, under an indenture agreement involving The Bank of New York Mellon as trustee. Legal opinions regarding the validity of the Notes and related matters have also been filed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.